Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Neovii
Neovii
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Removab
Catumaxomab
2009-04-20
Ascites
,
Neoplasms
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Catumaxomab
ovarian neoplasms
,
stomach neoplasms
,
adenocarcinoma
,
peritoneal neoplasms
,
ascites
,
ovarian epithelial carcinoma
,
carcinoma
,
neoplasms
Mycophenolate sodium
diabetic nephropathies
,
type 1 diabetes mellitus
Docusate
chronic obstructive pulmonary disease
,
cystic fibrosis
,
bronchiectasis
,
idiopathic pulmonary fibrosis
Transplatin
stomach neoplasms
,
adenocarcinoma
Antithrombin iii
graft vs host disease
Sodium chloride
graft vs host disease
,
chronic obstructive pulmonary disease
,
cystic fibrosis
,
bronchiectasis
,
idiopathic pulmonary fibrosis
,
myelodysplastic syndromes
,
myeloid leukemia acute
,
precursor cell lymphoblastic leukemia-lymphoma
ERTUMAXOMAB
breast neoplasms
Retinol
peritoneal neoplasms
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use